Challenges of Implementing New Remineralization Technologies

Aponte-Merced L, Navia JM, Gaffar A, Fine N (1987). Uptake of 45Ca from a topically-applied monofluorophosphate sodium fluoride calcium hydroxide dentifrice by rat enamel. Arch Oral Biol 32:17–20.

Baig A, He T (2005). A novel dentifrice technology for advanced oral health protection: A review of technical and clinical data. Compend Contin Educ Dent 26(9 Suppl 1):4S–11S.

Boneta AE, Neesmith A, Mankodi S, Berkowitz HJ, Sánchez L, Mostler K, et al. (2001). The enhanced anticaries efficacy of a sodium fluoride and dicalcium phosphate dihydrate dentifrice in a dual-chambered tube. A 2-year caries clinical study on children in the United States of America. Am J Dent 14(Spec No):13–17.

Chow LC, Takagi S, Carey CM, Sieck BA (2000). Remineralization effects of a two-solution fluoride mouthrinse: an in situ study. J Dent Res 79:991–995.

Chow LC, Takagi S, Frukhtbeyn S, Sieck BA, Parry EE, Liao NS, et al. (2002). Remineralization effect of a low-concentration fluoride rinse in an intraoral model. Caries Res 36:136–141.

Collier WG (2002). Comments RE: Docket No. 80N-0042—Anticaries drug products for over-the-counter human use; use of intraoral appliance models for compliance with biological testing requirements; Request for information and comments. Food and Drug Administration, Dockets Management Branch.

Cummins D (1995). Working group report 3: role of models in assessing new agents for caries prevention. Adv Dent Res 9:338–339.

DiMasi JA, Hansen RW, Grabowski HG (2003). The price of innovation: new estimates of drug development costs. J Health Econ 22:151–185.

Directive 2003/15/EC of the European Parliament and of the Council. OJ L 66/26 11.3.2003, p.26–35. http://Europa.eu/enterprise/cosmetics/doc/200315/200315_en.pdf

Food and Drug Administration, HHS (2001). Anticaries drug products for over-the-counter human use; use of intraoral appliance models for compliance with biological testing requirements; Request for information and comments. Fed Register 66:52418–52420.

Food and Drug Administration, HHS (2005). Draft guidance for industry on gingivitis: development and evaluation of drugs for treatment or prevention; Docket No. 2005D–0240. Fed Register 70:37102.

Gaffar A, Blake-Haskins J, Mellberg J (1993). In vivo studies with a dicalcium phosphate dihydrate/MFP system for caries prevention. Int Dent J 43(1 Suppl 1):81S–88S.

Karlinsey RL, Mackey AC, Stookey GK, Pfarrer AM (2009a). In vitro assessments of experimental NaF dentifrices containing a prospective calcium phosphate technology. Am J Dent 22:180–184.

Karlinsey RL, Mackey AC, Stookey GK (2009b). In vitro remineralization efficacy of NaF systems containing unique forms of calcium. Am J Dent 22:185–188.

Mundorff-Shrestha SA, Proskin HM, Winston AE, Triol CW, Cornell G, Sharpe T (1999). Cariostatic effect of a two-part fluoride dentifrice in rats. J Clin Dent 10(Spec No):26–29.

Pessan JP, Sicca CM, de Souza TS, da Silva SM, Whitford GM, Buzalaf MA (2006). Fluoride concentrations in dental plaque and saliva after the use of a fluoride dentifrice preceded by a calcium lactate rinse. Eur J Oral Sci 114:489–493.

Pfarrer AM, McQueen CM, Lawless MA, Rapozo-Hilo M, Featherstone JD (2005). Anticaries potential of a stabilized stannous fluoride/sodium hexametaphosphate dentifrice. Compend Contin Educ Dent 26(9 Suppl 1): 41S–46S.

PhRMA (2001). Pharmaceutical industry profile. Washington, DC: Pharmaceutical Research and Manufacturers of America.

Proskin HM (1995). Statistical considerations related to the use of caries model systems for the determination of clinical effectiveness of therapeutic agents. Adv Dent Res 9:270–278; discussion 279–289.

Proskin HM, Chilton NW, Kingman A (1992). Interim report of the ad hoc committee for the consideration of statistical concerns related to the use of intra-oral models in submissions for product claims approval to the American Dental Association. J Dent Res 71(Spec Iss):949–952.

Public Citizen Congress Watch (2002). America’s other drug problem: a briefing book on the Rx drug debate. Wasington, DC: Public Citizen, Report #C9021.

Roberts AJ (1995). Role of models in assessing new agents for caries prevention—non-fluoride systems. Adv Dent Res 9:304–311; discussion 312–314.

Silva MF, Melo EV, Stewart B, De Vizio W, Sintes JL, Petrone ME, et al. (2001). The enhanced anticaries efficacy of a sodium fluoride and dicalcium phosphate dihydrate dentifrice in a dual-chambered tube. A 2-year caries clinical study on children in Brazil. Am J Dent 14(Spec No):19–23.

Sintes JL, Escalante C, Stewart B, McCool JJ, Garcia L, Volpe AR, et al. (1995). Enhanced anticaries efficacy of a 0.243% sodium fluoride/10% xylitol/silica dentifrice: 3-year clinical results. Am J Dent 8:231–235.

Sintes JL, Elías-Boneta A, Stewart B, Volpe AR, Lovett J (2002). Anticaries efficacy of a sodium monofluorophosphate dentifrice containing xylitol in a dicalcium phosphate dihydrate base. A 30-month caries clinical study in Costa Rica. Am J Dent 15:215–219.

Stookey GK (1984). Are all fluorides the same? In: Clinical uses of fluorides. Wei SHY, editor. Philadelphia: Lea & Febiger, pp. 105–131.

Stookey GK, Warrick JM, Miller LL, Greene AL (1995). Animal caries models for evaluating fluoride dentifrices. Adv Dent Res 9:198–207

Stookey GK, Mau MS, Isaacs RL, Gonzalez-Gierbolini C, Bartizek RD, Biesbrock AR (2004). The relative anticaries effectiveness of three fluoride-containing dentifrices in Puerto Rico. Caries Res 38:542–550.

Sullivan RJ, Masters J, Cantore R, Roberson A, Petrou I, Stranick M, et al. (2001). Development of an enhanced anticaries efficacy dual component dentifrice containing sodium fluoride and dicalcium phosphate dihydrate. Am J Dent 14(Spec No):3–11.

Tinanoff N (1984). Stannous fluoride in clinical dentistry. In: Clinical uses of fluorides. Wei SHY, editor. Philadelphia: Lea & Febiger, pp. 25–34.

Vogel GL, Zhang Z, Carey CM, Ly A, Chow LC, Proskin HM (2000). Composition of plaque and saliva following use of an alpha-tricalcium-phosphate-containing chewing gum and a subsequent sucrose challenge. J Dent Res 79:58–62.

Vogel GL, Chow LC, Carey CM, Schumacher GE, Takagi S (2006a). Effect of a calcium prerinse on salivary fluoride after a 228-ppm fluoride rinse. Caries Res 40:178–180.

Vogel GL, Shim D, Schumacher GE, Carey CM, Chow LC, Takagi S (2006b). Salivary fluoride from fluoride dentifrices or rinses after use of a calcium pre-rinse or calcium dentifrice. Caries Res 40:449–454.

Wefel JS, Stanford CM, Ament DK, Hogan MM, Harless JD, Pfarrer AM, et al. (2002). In situ evaluation of sodium hexametaphosphate-containing dentifrices. Caries Res 36:122–128.

White DJ (1992). The comparative sensitivity of intra-oral, in vitro, and animal models in the ‘profile’ evaluation of topical fluorides. J Dent Res 71(Spec Iss):884–894.

White DJ (1995). The application of in vitro models to research on demineralization and remineralization of the teeth. Adv Dent Res 9:175–193; discussion 194–197

White DJ (2002). A new and improved “dual action” whitening dentifrice technology—sodium hexametaphosphate. J Clin Dent 13:1–5.